Agios hit a setback for Tibsovo in Europe this year however after the EMA rejected the marketing application for the drug. Servier is paying $1.8 billion upfront for the oncology assets, with the ...

the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond concluded its attempt to push two cancer drugs through ...

Now, Servier says it has data from a phase 3 trial in the previously-untreated group that could allow it to have another go at European approval, and also support the drug's use as part of a first ...

Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. | Servier’s decision to exit a Parkinson’s disease pact has ...

“Servier’s commitment to innovation and deep ... the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe ...

Per the terms of the sale agreement between the two companies, Servier made a milestone payment ... contingent on the FDA’s approval for the drug. Management intends to utilize the above funds ...

Servier will lead the development activities ... Also Read: Black Diamond Therapeutics’ Lead Drug Candidate Shows Initial Anti-Tumor Activity In Certain Type Of Lung Cancer Resistant To ...

DelveInsight's "TIBSOVO Market Size, Forecast, and Market Insight Report" highlights the details around TIBSOVO, the first ...

SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...